Literature DB >> 16565717

Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia.

Annett Spudich1, Ertugrul Kilic, Hongyi Xing, Ulkan Kilic, Katharina M Rentsch, Heidi Wunderli-Allenspach, Claudio L Bassetti, Dirk M Hermann.   

Abstract

The blood-brain barrier possesses active transporters carrying brain-permeable xenobiotics back into the blood against concentration gradients. We demonstrate that multidrug resistance transporter (Mdr)-1 is upregulated on capillary endothelium after focal cerebral ischemia; moreover, Mdr-1 deactivation by pharmacological inhibition or genetic knockout preferably enhances the accumulation and efficacy of two neuroprotectants known as Mdr-1 substrates in the ischemic brain. We predict that Mdr-1 inhibition may greatly facilitate neuroprotective therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565717     DOI: 10.1038/nn1676

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  51 in total

1.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

2.  Identification of P-glycoprotein co-fractionating proteins and specific binding partners in rat brain microvessels.

Authors:  Margaret E Tome; Charles P Schaefer; Leigh M Jacobs; Yifeng Zhang; Joseph M Herndon; Fabian O Matty; Thomas P Davis
Journal:  J Neurochem       Date:  2015-04-21       Impact factor: 5.372

3.  Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Authors:  Dirk M Hermann
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 4.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

5.  Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier.

Authors:  Yutaro Hoshi; Yasuo Uchida; Masanori Tachikawa; Sumio Ohtsuki; Pierre-Olivier Couraud; Takashi Suzuki; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

6.  Role of Nogo-A in neuronal survival in the reperfused ischemic brain.

Authors:  Ertugrul Kilic; Ayman ElAli; Ulkan Kilic; Zeyun Guo; Milas Ugur; Unal Uslu; Claudio L Bassetti; Martin E Schwab; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

Review 7.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

8.  Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier.

Authors:  David B Banks; Gary Ny Chan; Rebecca A Evans; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-27       Impact factor: 6.200

9.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

Review 10.  Transporters as Drug Targets in Neurological Diseases.

Authors:  H Qosa; L A Mohamed; S Alqahtani; B S Abuasal; R A Hill; A Kaddoumi
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.